Oxford BioDynamics Plc present strong data at ASH Summit

Dr Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics, commented:

“There have been many exciting breakthroughs in the immunotherapy of cancerous and non-cancerous hematologic diseases, including immune checkpoint inhibitors. However, questions of safety and efficacy present significant challenges, with a high demand for molecular biomarkers that may help to predict clinical outcomes.

Our aim is to develop and deliver non-invasive prognostic biomarkers in this fast developing and competitive field, and we were pleased to present strong data at this ASH Summit. Our EpiSwitch™ technology could stratify and predict which patients would not respond adequately to checkpoint inhibitor therapy, with high accuracy. We are very pleased with the interest our data have generated amongst the leaders in the field.

We believe that successful epigenetic stratifications of patients using EpiSwitch™ biomarkers could help improve understanding of the regulatory mechanisms in blood disorders, gain valuable insights into new targets and treatment designs, as well as help improve patients outcomes by supporting clinical decisions on the most appropriate and effective treatment option.”

Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has presented its latest EpiSwitch™ data in a plenary talk at the American Society of Hematology (ASH) Summit on Emerging Immunotherapies for Hematologic Diseases, 12-13 July 2018, Washington DC, entitled: “Chromosome Conformation Monitoring for Prognostic Stratifications of Non-responders to Cancer Immunotherapies: Deconvolution of Epigenetic data with EpiSwitch™.”

Dr Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics, presented data on prognostic blood-based stratifications of patients with a common type of Non-Hodgkin lymphoma, and on predictive biomarkers for response to treatment with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1. Data presented from several indications successfully demonstrated that EpiSwitch™ epigenetic biomarkers identified in patients’ blood could help identify patients that will not respond adequately to anti-PD-1 or anti-PD-L1 monotherapy. Based on further analysis of more than 126 patients, this validation study demonstrated 94% accuracy in predicting response to the anti-PD-L1 treatment.

Immunotherapy, particularly immune checkpoint inhibitor PD-1/PD-L1 treatments, is a type of therapy that harnesses a person’s immune system to fight cancer cells. Lymphomas represent a broad range of blood cancers based on diseases of white cells. While Hodgkin lymphomas show good response to immunotherapies, response and efficacy in other lymphomas remain modest at best. OBD is actively involved in the fast moving field of immunotherapy, with a number of proprietary and commercial studies based on immune checkpoint inhibitors, monotherapies and combination therapies, for a growing list of cancer types.

Through the development of epigenetic biomarkers, OBD’s EpiSwitch™ technology can help pharmaceutical and biotechnology companies bring drugs to the market sooner through personalising drugs to patients most likely to respond, delivering better clinical outcomes.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    What is EpiSwitch and how is it used?

    Grounded in Epigenetics Oxford BioDynamics’ EpiSwitch technology is based on epigenetics: mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune diseases, neurologic

    Oxford BioDynamics

    FDA publishes guidance to help in developing new ALS therapies

    After gathering input from patients, researchers, and advocates, the U.S Food and Drug Administration (FDA) has released new guidance on the development of therapies for amyotrophic lateral sclerosis (ALS). Among its recommendations, it is advising more communication with

    Oxford BioDynamics

    Qualtrax Boosts Oxford BioDynamics Efficiencies

    Businesses involved in areas such as the pharmaceutical sector must demonstrate the highest levels of compliance, traceability and quality. Given the large volumes of documents generated by such organisations, important tasks such as keeping track of

    Oxford BioDynamics

    What you need to know about rheumatoid arthritis

    Rheumatoid arthritis (RA) is a chronic disease that affects the joints throughout your body. It often starts in the hands and feet RA is an autoimmune disease, it happens when your immune system attacks your own cells. While

    Oxford BioDynamics

    Want to Slow Down Your ALS? Try Smiling!

    What does smiling have to do with ALS? Or happiness, contentment, or feeling positive? These expressions of our sense of well-being are important to those of us living with ALS. According to a study of 224 ALS patients, participants

    Oxford BioDynamics

    How does alcohol affect rheumatoid arthritis?

    Drinking alcohol in moderation is typically safe for people with rheumatoid arthritis (RA). According to the Arthritis Foundation, drinking alcohol in moderation is usually safe, and may even reduce certain types of inflammation. Some research says that small

    Oxford BioDynamics

    Ice Bucket Challenge Creator Continues To Inspire

    A Westchester man battling ALS is fighting for a cure and one way he hopes to do that is by bringing back the ice bucket challenge. Pat Quinn was diagnosed with the deadly degenerative disease in

    Oxford BioDynamics

    MND Association welcomes report on benefits and terminal illness

    A report revealing terminally ill people face devastating and far-reaching financial hardship because of a ‘made-up policy fudge’ has been welcomed by the Motor Neurone Disease (MND) Association. The All Party Parliamentary Group for Terminal Illness

    Oxford BioDynamics

    Having this temperature in your joints must NOT be ignored

    Arthritis is a type of inflammatory autoimmune disease and is a musculoskeletal condition which is caused by the body’s joints. The areas most commonly affected include the hands, fingers, hips, knees and spine. The disease commonly affects